The reality of LOH-symptoms
|
|
- Verity Kennedy
- 5 years ago
- Views:
Transcription
1 The reality of LOH-symptoms PRISM IV Bruges, Belgium September 25-26, 2014 Dr. Herman Leliefeld Androsmannenkliniek The Netherlands
2 The reality of LOH symptoms
3 male external & internal genitalia Testosterone Corona et al., J Sex Med 2011;8:3869.
4 Age, < 50 y, N=869 Age >50 y, N=606 Araujo et al. J Clin Endocrinol Metabolism 2007,
5 The reality of LOH symptoms
6 Three less specific symptoms of LOH Osteoporosis Overweight Depression and: Mortality!
7 T is metabolized to 5alfaDHT and 17betaEstradiol
8 Low trauma fracture, low bone mineral Density 1.Osteoporosis in men 10 years later than in women 2.More hipfractures in men with low testosteron High costs because of hip- and lumbar spine fractures Meier C, Arch Int Med 2008;168;
9 Three less specific symptoms of LOH Osteoporosis Overweight Depression and: Mortality!
10 European Male Aging Study (EMAS) Relation between Age, BMI and Testosterone Wu FCW et al. J Clin Endocrin Metab 93(7): (2008)
11 The risks of a high BMI: 30kg/m 2 = Obese Cohort study :6502 men born in 1955 in Denmark Follow up :33 years Normal weight: 5407 men =83% Underweight : 353 men =5% Overweight : 639 men=10% Obese : 97 men=1,5% Schmidt M, BMJ Open 2013:3(4)
12 Results Danisch Study, Schmidt, BMJ Open 2013 % of DM-2, hypertension, myocardial infarction, venous tromboembolism or death before the age of 55 years Normal weight : 20 % Overweight : 31 % Obese men : 48%
13 Results Danisch Study, Schmidt, BMJ Open 2013 Event Rate : DM-2 RR MI Tromboemb. Death Normal weight : Overweight : 3,1 2 1,1 0,9 0,9 Obese men : 8,2 2,0 2,5 4,7 2,1 Absolute risk increase of 30% in obese men
14 Association Mortality with Overweight and Obesity Meta-analysis by K. Flegal, JAMA, 2013, 309, PubMed and EMBASE search articles, - 97 elegible : combining a sample size of: - 2,88 million individuals deaths
15 Association Mortality with Overweight and Obesity Flegal, K, JAMA 2013
16 Lower mortality in overweight and grade 1 obese men/women Possible explanations: -Earlier presentation of heavier patients -Greater likelihood of receiving optimal medical treatment -Benefits of higher metabolic reserves Flegal K, JAMA 2013 ; 309
17 Low Testosterone as a risk factor for CV-Mortality Meta-analysis by Corona G, Eur J of Endocr, 2011, 165, Medline search articles, - 70 elegible
18 Lower T as a risk factor for (cardiovascular)mortality Corona G, 2011
19 LOH and all-cause mortality in men with DM-2 Muraleedharan V, T Hugh Jones, Nottinghamshire, UK -6-year follow up -n=581 men with type 2 diabetes -Mortality rates compared between: TT 10,4 nmol/l : n=343: 9% TT 10,4 nmol/l : n=238: 17,2% Eur J Endocrin,
20 Figure 1 Multivariate-adjusted survival curves using Cox regression model for all-cause mortality based on total testosterone (TT). Hazard Ratio: % 17,2% Muraleedharan V et al. Eur J Endocrinol 2013;169: European Society of Endocrinology
21 Figure 3 Multivariate-adjusted survival curves using Cox regression model for treated and untreated groups compared with those with normal testosterone. 64 with TRT: 9,3% Effect of TRT on mortality in 238 men with low T Mean duration of TRT: 41 months Hazard ratio:2,3 for decreased survival 340 normal TT: 9,1% 174 without TRT: 20,1% Muraleedharan V et al. Eur J Endocrinol 2013;169: European Society of Endocrinology
22 TRT increases the risk of a cardiovascular mortality 4 studies: 1.Basaria, NEJM 2010;363; Xu, BMC Medicine 2013; 11: Vigen, JAMA 2013; 310: Finkle, PLoS ONE 2014;9(1); e85805 Generated considerable concern regarding safety of TRT among global medical community and lay public
23
24 Death by Testosterone? We Think Not! The Journal of Sexual Medicine Volume 11, Issue 3, pages , 4 MAR 2014 DOI: /jsm
25 Overview of the literature by Traish J Sex Med 2014
26 Three less specific symptoms of LOH Osteoporosis Overweight Depression and: Mortality!
27 2-year incidence diagnosis depression ICD-9-CM Increased incidence of depression in hypogonadism Shores et al Arch Gen Psychiat 2004 N = 278 men > 45 years initially without depression Total T nmol / L
28 Symptomprävalenz % Depression Zitzmann et al. JCEM Overall Somer s d: p < T<8 T:8-10 T:10-12 T:12-15 T:15-20 T 20 Sextile Total T (nmol/l) n (patients) (Total n = 434)
29 The reality of LOH-symptoms Symptoms not very specific, but Symptoms necessary for the Diagnosis LOH Symptoms are relatively mild, insidious and difficult to recognize but Often bothersome, and frustrating because of an overall decrease of the quality of life (until death!)
30 Are symptom questionnaires of any help? ADAM questionnaire 2000 Good sensitivity AMS-questionnaire 2004 Low specificity NERI Hypogonadism screener 2011 ANDROTEST /70%
31 AMS questionnaire 17 questions 5 points each In total 85 points
32 Frequency distribution of complaints by AMS in a normal population vs patients before and after 12 weeks of TRT no/little mild moderate severe 10 0 standard population before therapy after therapy Moore C et al, Eur Urol 46:80-87(2004)
33 New Definition of LOH: EMAS, Wu,NEJM 2010 Syndromic association between Triad of sexual symptoms and Biochemical condition -Low libido -Reduced spontaneous erections -Reduced sex-related erections -Morning Total T < 11 nmol/l (<3.1ng/ml) -Free T < 222,2 pmol/l (<64 pg/ml)
34 So, are the symptoms real?? Answer: Yes, they are Are the symptoms specific for LOH? No, only for a triad of three sexual symptoms
35 Is this the End? Pieter Brueghel de Oude
36 Or like this? Mick Jagger, 70 years The End
37 Gender as a risk factor for cardiovascular mortality In General in Europe: before 65 years before 75 years Men 1 in 8 1 in 4 Women 1 in 20 1 in 6 Atlas of Health in Europe, WHO 2008
PRISM Bruges June Herman Leliefeld Urologist. The Netherlands
PRISM Bruges 25-26 June 2015 Herman Leliefeld Urologist The Netherlands Guidelines EAU 2015: a rich source of Knowledge! Epidemiology/ Aetiology / Pathology Diagnostic evaluation Disease management Follow-Up
More informationUpdate on diagnosis and complications of adult and elderly male hypogonadism
Hypoandrogenism in the elderly: to treat or not to treat? 12 th Italian AME Meeting; 6 th joint Meeting with AAC Bari november 10th Update on diagnosis and complications of adult and elderly male hypogonadism
More informationDoes TRT Induce Prostate Cancer?
Does TRT Induce Prostate Cancer? Prism VI, Bruges, Belgium 21-22November 2014 Herman Leliefeld, Urologist, Utrecht The Netherlands Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there
More informationAn Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health
An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health KEVIN R. LOUGHLIN MD,MBA Harvard Medical School Boston, MA THE WEAKER SEX-MALES LIFE EXPECTANCY
More informationTestosterone Therapy in Men An update
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
More informationOutline. Classic Androgen deficiency. Cardiovascular Risk and Testosterone Fact vs Fiction. Professor Robert I McLachlan AM, FRACP, PhD
Health Ed Brisbane Saturday 27 th October 2018 Cardiovascular Risk and Testosterone Fact vs Fiction Professor Robert I McLachlan AM, FRACP, PhD Hudson Institute of Medical Research, Monash University Department
More informationTESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER?
TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY (TRT) Nuno Tomada, MD, PhD Department of Urology of Hospital S. João Faculty of
More informationDisclosures. Faculty 3/5/18. Testosterone, the FDA and CVD Risk Controversies. Matt Rosenberg, MD Director of Mid-Michigan Health Centers Jackson, MI
Testosterone, the FDA and CVD Risk Controversies Faculty Matt Rosenberg, MD Director of Mid-Michigan Health Centers Jackson, MI 2 Disclosures Matt Rosenberg, MD serves on the advisory board for Bayer,
More informationDisclosures. Advisory Boards 6/10/2014
Massachusetts Medical Society 12 th annual Men s Health Symposium 11 June 2014 Testosterone and Cardiovascular Disease Where Does The Real Answer Lie? Andre Guay MD, FACP, FACE, IF (Ret) Director, Center
More informationPoint-Counterpoint: Late Onset Hypogonadism (LOH)
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
More informationEFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE
EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE Matthew Ho, PGY-2 Department of Urologic Sciences University of British Columbia OBJECTIVES 1. Review the characteristics
More informationDisclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
More informationTestosterone Replacement Therapy for Hypogonadism: Learning Objectives. What Is the Evidence? Is It Safe? Case Study. Case Study contd.
4 4:4pm Testosterone Therapy: Examining the Evidence SPEAKER Culley Carson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Culley Carson, MD: Consultant
More informationHHS Public Access Author manuscript Int J Impot Res. Author manuscript; available in PMC 2015 September 01.
Testosterone Therapy and Mortality Risk Michael L. Eisenberg, MD 1, Shufeng Li, MS 2, Danielle Herder, MD 3, Dolores J. Lamb, PhD 4, and Larry I. Lipshultz, MD 4 1 Assistant Professor, Departments of Urology
More informationLow T? Late Onset Hypogonadism
University of Vermont ScholarWorks @ UVM Family Medicine Clerkship Student Projects College of Medicine 2014 Low T? Late Onset Hypogonadism Cheng-Wei Huang University of Vermont Follow this and additional
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationTestosterone and PDE5 inhibitors in the aging male
Testosterone and PDE5 inhibitors in the aging male Francesco Romanelli Department of Experimental Medicine Medical Pathophysiology, Food Science and Endocrinology Section Sapienza University of Rome 3005
More informationErectile Dysfunction, Cardiovascular Risk and
Erectile Dysfunction, Cardiovascular Risk and Testosterone National Lipid Association (NLA) 2016 Fall Clinical Update August 26-28, 2016 Amelia Island, Fl Robert A. Kloner MD, PhD Director of the Cardiovascular
More informationPresent and future association between obesity and hypogonadism in Italian male
ORIGINAL PAPER DOI: 10.4081/aiua.2014.1.26 Present and future association between obesity and hypogonadism in Italian male Valentina Boddi 1, Valeria Barbaro 2, Paul Mc Nieven 3, Mario Maggi 1, Carlo Maria
More informationA dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male
Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.
More informationNEW DEVELOPMENTS: T & CVD FDA & THE T TRIALS
NEW DEVELOPMENTS: T & CVD FDA & THE T TRIALS 2017 UPDATE FDUS Martin Miner MD Clinical Professor of Family Medicine and Urology Co-Director The Men s Health Center The Miriam Hospital Warren Albert School
More informationTake-Home Messages: Androgens
Take-Home Messages: Androgens Anthony J. Bella MD, FRCSC Greta and John Hansen Chair in Men s Health Research Division of Urology, Department of Surgery University of Ottawa SUMMARY SLAMS Symposium Clinical
More informationLate onset hypogonadism
Late onset hypogonadism Farrukh Javid Male Menopause Clinical AND biochemical syndrome Testosterone levels decline by 0.4-3% per year after the age of 30, as opposed to the more rapid decline that occurs
More informationBIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE
Authoriser: Moya O Doherty Page 1 of 7 BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE The purpose of this protocol is to describe common tests used for the investigation
More informationVitamin D supplementation of professionally active adults
Vitamin D supplementation of professionally active adults VITAMIN D MINIMUM, MAXIMUM, OPTIMUM FRIDAY, SEPTEMBER 22 ND 2017 Samantha Kimball, PhD, MLT Research Director Pure North S Energy Foundation The
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationMetastatic disease. 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942
Prostate cancer Metastatic disease 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942 Impact of early prostate cancer 12 10 8 6 4 2 0 70-80 years 60-70 years
More informationWhy Do We Treat Obesity? Epidemiology
Why Do We Treat Obesity? Epidemiology Epidemiology of Obesity U.S. Epidemic 2 More than Two Thirds of US Adults Are Overweight or Obese 87.5 NHANES Data US Adults Age 2 Years (Crude Estimate) Population
More informationHypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.
Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology
More informationProf Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA
Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA Prevailing context Increase number of men who are potential candidates for Testosterone Replacement Therapy
More informationEmerging Areas Relating Vitamin D to Health
ILSI SEA Region Vit D Conference, Australia, June 2012 (www.ilsi.org/sea Region) Emerging Areas Relating Vitamin D to Health Peter R Ebeling MD FRACP NorthWest Academic Centre and Dept Endocrinology The
More informationHypogonadism in Men. CME Away India & Sri Lanka March 23 - April 7, 2018
Hypogonadism in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017
More informationHYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY)
HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) DEFECT OF THE REPRODUCTIVE SYSTEM THAT RESULTS IN LACK OF FUNCTION OF THE GONADS (Wikipedia) REDUCTION
More informationFOR CONSUMERS AND PATIENTS
AVAILABILITY OF VITAMIN D FOR CONSUMERS AND PATIENTS Prof. Heike A. Bischoff-Ferrari, MD, DrPH Centre on Aging and Mobility, University of Zurich Dept. of Rheumatology, University Hospital Zurich Overview
More informationVitamin D and Calcium Therapy: how much is enough
Vitamin D and Calcium Therapy: how much is enough Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco DISCLOSURE Nothing to disclose 1 RECOMMENDATIONS
More informationThe Endocrine Society Guidelines
Vitamin D and Calcium Therapy: how much is enough DISCLOSURE Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco Nothing to disclose RECOMMENDATIONS
More informationTestosterone therapy in the new era of Food and Drug Administration oversight
Review Article Testosterone therapy in the new era of Food and Drug Administration oversight Bethany Desroches 1, Taylor P. Kohn 2, Charles Welliver 3, Alexander W. Pastuszak 1,4 1 Scott Department of
More informationTRT and localized protate cancer
TRT and localized protate cancer Frans M. J. Debruyne Professor of Urology PRISM BRUGES Increased risk of prostate cancer with TRT? Prostate cancer Testosterone and Prostate Cancer There appears to be
More informationHow to treat: TRT modalities and formulations
How to treat: TRT modalities and formulations Paul PIETTE, PharmD Senior Research Fellow Clinique Antoine Depage - Belgium ppiette@besins-healthcare.com Bruges 2014, May 15 th Testosterone-replacement
More informationCritical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death. Debra Moy Faculty of Pharmacy University of Toronto
Critical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death Debra Moy Faculty of Pharmacy University of Toronto Goal To provide practitioners with a systematic approach to evaluating a meta analysis
More informationCentral hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction
Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction N.Skliros, N.Ioakeimidis, D.Terentes-Printzios, C.Vlachopoulos Cardiovascular Diseases and Sexual Health
More informationCardiac Safety Signals: Case Examples
Cardiac Safety Signals: Case Examples Testosterone Peripherally-acting mu-receptor antagonist PAMORAs Dabigatran (Pradaxa) 2 Testosterone Testosterone replacement therapy is approved for men with low levels
More informationSupplementary Online Content
Supplementary Online Content Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B 1. JAMA. 9;3(19):119-1. etable 1. Circulating Levels of B
More informationSchöttker et al. BMC Medicine (2016) 14:26 DOI /s
Schöttker et al. BMC Medicine (2016) 14:26 DOI 10.1186/s12916-016-0570-1 RESEARCH ARTICLE HbA 1c levels in non-diabetic older adults No J-shaped associations with primary cardiovascular events, cardiovascular
More informationSystematic Review & Course outline. Lecture (20%) Class discussion & tutorial (30%)
Systematic Review & Meta-analysisanalysis Ammarin Thakkinstian, Ph.D. Section for Clinical Epidemiology and Biostatistics Faculty of Medicine, Ramathibodi Hospital Tel: 02-201-1269, 02-201-1762 Fax: 02-2011284
More informationPrimary Care Updates ACP conference 2015
Primary Care Updates ACP conference 2015 Richard Rose, MD FACP Assistant Professor University of Utah Department of General Internal Medicine VAMC - Internal Medicine Nothing to disclose Conflicts of interest
More informationVascular Diseases. Overview: Selected Slides
Vascular Diseases Overview: Selected Slides Total deaths and change in vascular death rates
More informationOsteoporosis in Men Professor Peter R Ebeling
Osteoporosis in Men MD FRACP Head, Department of Medicine, School for Clinical Sciences Monash Health Translation Precinct Monash University, Clayton, Victoria 1 MonashHealth Potential Conflicts Departmental
More informationTestosterone and obesity. Referent Prof. Dr. Michael Zitzmann
Testosterone and obesity Referent Prof. Dr. Michael Zitzmann Transparenzinformation arztcme Die Bundesärztekammer und die Landesärztekammer Hessen fordern zur Schaffung von mehr Transparenz beim Sponsoring
More informationLate Onset Hypogonadism. Toh Charng Chee Hospital Selayang
Late Onset Hypogonadism Toh Charng Chee Hospital Selayang Introduction Although suppressed serum testosterone (T) is common in ageing men, only a small proportion of them develop the genuine syndrome of
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationManaging Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University
Managing Testosterone Deficiency: A Practical Guide John Grantmyre MD Professor of Urology Dalhousie University 1 2 Case Study #1 A 59-Year-Old Man with Erectile Dysfunction 3 Case History Robert is a
More informationAlternative management of hypogonadism Tamoxifen. Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY
Alternative management of hypogonadism Tamoxifen Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY eajannini@gmail.com What hypogonadism is? What hypogonadism is? It is an empty glass The two
More informationIan Eardley Department of Urology, Leeds Teaching Hospital Trust
Ian Eardley Department of Urology, Leeds Teaching Hospital Trust Assessment of the man with ED Medical therapy for man with ED What to do when pills fail Sexual stimulus Neural pathways Neurotransmitter
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationRecommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men
Recommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men Bruno Lunenfeld, George Mskhalaya, Svetlana Kalinchenko, Yulia Tishova, Michael Zitzmann, Stefan
More informationThe clinical importance of testosterone in men with type 2 diabetes
22 The clinical importance of testosterone in men with type 2 diabetes GEOFF HACKETT Although the association of low testosterone with type 2 diabetes is well established, testosterone levels are not routinely
More informationPCa Commentary. Prostate Cancer? Where's the Meat? - A Collection of Studies Supporting the Safety of Its Use. Seattle Prostate Institute CONTENTS
Volume 70 July - August 2011 PCa Commentary SEATTLE PROSTATE INSTITUTE CONTENTS TESTOSTERONE REPLACEMENT in Hypogonadal Men with Treated and Untreated Prostate Cancer? 1 TESTOSTERONE REPLACEMENT in Hypogonadal
More informationO futuro da Ciência e dos Dados Científicos
IX Congresso Nacional O futuro da Ciência e dos Dados Científicos Prof. Luis A. Moreno Determinants and risk factors for cardiovascular diseases (Tzoulaki I et al. Circulation 2016; 133: 2314-2333) Adjusted
More informationRelative Risk of Major Risk of Chronic Major Disease Catego ries, by Gender and Gender and verag e Drinkin e Dr g Catego Females Males Disease Disea
38 th IMAG Conference, Amsterdam, October 13-14, 14, 2014 International Meeting on Alcohol and Global Health Overview: All-Cause Mortality Wolfgang Koenig MD, FRCP, FESC, FACC, FAHA Dept. of Internal Medicine
More informationTestosterone Replacement Therapy & Monitoring in HIV Infected Men. Adam B. Murphy, MD, MBA, MSCI October 29, 2014
Testosterone Replacement Therapy & Monitoring in HIV Infected Men Adam B. Murphy, MD, MBA, MSCI October 29, 2014 Acknowledgement Ramona Bhatia MD (HIV Research Fellow, First Author) Chad Achenbach MD (HIV
More informationLate onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital
Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,
More informationNutritional Considerations with Obesity and Bariatric Surgery. Presented by Dr. Ron Grabowski
Nutritional Considerations with Obesity and Bariatric Surgery Presented by Dr. Ron Grabowski January 25, 2010 Nutritional Considerations with Obesity and Bariatric Surgery Presented by Dr. Ron Grabowski
More informationSupplemental tables: Abbreviations:
Supplemental tables: Abbreviations: Osteoprotegerin (OPG), Receptor Activator of Nuclear factor Kappa beta Ligand (RANKL), fibroblast growth factor-23 (FGF-23), C-terminal cross-linked telopeptide of type-i
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationTestosterone and the Prostate
Testosterone and the Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David and Vicki M. Crawford Endowed Chair in Urologic Oncology University
More informationMetabolically healthy obesity and NAFLD
News & Views Metabolically healthy obesity and NAFLD Giovanni Targher and Christopher D. Byrne Giovanni Targher is at the Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University
More informationEvery obese male with type 2 diabetes should be screened for hypogonadism
Every obese male with type 2 diabetes should be screened for hypogonadism FOR Professor T Hugh Jones Consultant Physician & Endocrinologist, Robert Hague Centre for Diabetes and Endocrinology, Barnsley
More informationOVERVIEW WOMEN S HEALTH: YEAR IN REVIEW
OVERVIEW WOMEN S HEALTH: YEAR IN REVIEW Judith Walsh, MD, MPH Professor of Medicine UCSF Update in Women s Health for SGIM Drs. Mary Beattie and Pam Charney Review of literature from March, 2008 through
More informationSMSNA Hypogonadism Colloquium: Update
SMSNA Hypogonadism Colloquium: Update Arthur L. (Bud) Burnett, M.D., M.B.A., F.A.C.S. Patrick C. Walsh Distinguished Professor of Urology The James Buchanan Brady Urological Institute Johns Hopkins Medicine
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationWhat Is the Low T Syndrome? Is Testosterone Supplementation Safe?
What Is the Low T Syndrome? Is Testosterone Supplementation Safe? UCSF Osher Mini Medical School March 7, 2018 Dolores Shoback, MD Staff Physician SF-VAMC Professor of Medicine, UCSF No disclosures or
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
TESTOSTERONE REPLACEMENT THERAPY: ANDRODERM transdermal patch ANDROGEL pump transdermal gel and transdermal gel AXIRON transdermal solution FORTESTA transdermal gel NATESTO nasal gel STRIANT buccal mucoadhesive
More informationTestosterone Deficiency Syndrome. Time for Proper Personalised Care
Prof Geoffrey Hackett Good Hope Hospital Sutton Coldfield Testosterone Deficiency Syndrome Time for Proper Personalised Care BSSM Testosterone Guidelines 2017 www.bssm.org.uk Recommendations Diagnosis
More informationRegister now at
Register now at www.issuesandanswers.org Inspiring programme, great speakers & 6 CPD points! MAKING BEST PRACTICE EVERYDAY PRACTICE Sex, hormones & the heart Professor Mike Kirby FRCP University of Hertfordshire
More informationRisk Stratification of Surgical Intensive Care Unit Patients based upon obesity: A Prospective Cohort Study
Risk Stratification of Surgical Intensive Care Unit Patients based upon obesity: A Prospective Cohort Study DR N O M A N S H A H Z A D R E S I D E N T G E N E R A L S U R G E R Y A G A K H A N U N I V
More information9/2/2016. Faculty. Learning Objectives. Disclosures. Prevalence of Hypogonadism. Prevalence of HG (cont)
Faculty Testosterone Replacement Therapies: Mitigating Cardiometabolic Risks Associated with Hypogonadism Pamela Ellsworth, MD Professor of Urology University of Massachusetts Medical School Vice Chair,
More informationISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN
International Society for Sexual Medicine - www.issm.info ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN Version: September 2015 What is testosterone deficiency? Testosterone deficiency
More informationTHE RELEVANCE OF TESTOSTERONE THERAPY IN MANAGING PATIENTS WITH ERECTILE DYSFUNCTION
THE RELEVANCE OF TESTOSTERONE THERAPY IN MANAGING PATIENTS WITH ERECTILE DYSFUNCTION Aksam A. Yassin MD PhD EdD FEBU Professor of Urology & Human Sexuality Institute of Urology & Andrology, Segeberger
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationRESEARCH. Dagfinn Aune, 1,2 Abhijit Sen, 1 Manya Prasad, 3 Teresa Norat, 2 Imre Janszky, 1 Serena Tonstad, 3 Pål Romundstad, 1 Lars J Vatten 1
open access BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants Dagfinn Aune, 1,2 Abhijit
More informationCorporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency
More informationTestosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E
Testosterone Treatment: Myths Vs Reality Fadi Al-Khayer, M.D, F.A.C.E The Biological Functions of Testosterone in Men Testosterone is essential to the musculoskeletal and metabolic systems throughout a
More informationHORMONE THERAPY IN AGING MALE ATHLETES
DISCLOSURES HORMONE THERAPY IN AGING MALE ATHLETES No relevant affiliations or financial interests When, Why and is it Safe? OBJECTIVES Summarize the benefits of optimizing hormone balance Examine the
More informationVitamin D: Conflict of Interest Statement Corporate. Outline 7/5/2016
Vitamin D: What s New and Not? Clifford J Rosen MD Maine Medical Center Research Institute rosenc@mmc.org Conflict of Interest Statement Corporate NO STOCKS or EQUITY Editor UpToDate, New England Journal
More informationTestosterone Therapy and the Prostate. Frans M.J. Debruyne Professor of Urology The Netherlands
Testosterone Therapy and the Prostate Frans M.J. Debruyne Professor of Urology The Netherlands TRT- Risks Prostate ( Cancer, BPH )? Cardiac? Lipids? Polycythemia Sleep apnea Gynecomastia Edema Testosterone
More informationSupplementary Online Content
Supplementary Online Content Åsvold BO, Vatten LJ, Bjøro T, et al; Thyroid Studies Collaboration. Thyroid function within the normal range and risk of coronary heart disease: an individual participant
More informationDiagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes
Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Adrian Dobs, M.D., M.H.S. Professor of Medicine and Oncology The Johns Hopkins University School of Medicine
More informationPresenter Disclosure Information Karine Sahakyan, MD, PhD, MPH
Presenter Disclosure Information Karine Sahakyan, MD, PhD, MPH Disclosed no conflict of interest Normal-weight central obesity and cardiovascular mortality risk in the US population K. Sahakyan, VK. Somers,
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationNutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Objectives
Nutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Bess Dawson-Hughes, MD Disclosures: Amgen, DSM, Nestle, Opko, Pfizer, Roche, Tricida Interrelationships of muscle
More informationHypogonadism and erectile dysfunction as harbingers of systemic disease
Review Article Hypogonadism and erectile dysfunction as harbingers of systemic disease Kelly A. Chiles 1,2 1 Department of Urology, George Washington University, Washington, DC, USA; 2 Weill Cornell Medical
More informationTestim 1 Gel: Review of Clinical Data
European Urology Supplements European Urology Supplements 4 (2005) 24 30 Testim 1 Gel: Review of Clinical Data Tom A. McNicholas* Department of Urology, Lister Hospital, Corey s Mill Lane, Stevenage, Hertfordshire
More informationAndrogen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital
Androgen deficiency Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital Outline Pathological androgen deficiency - Background, causes, interpretation - Indications for treatment Androgen
More informationDiagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ)
Diagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ) Alvaro Morales CM MD, Richard A. Bebb MD, Priya Manjoo MD MSc, Peter Assimakopoulos MD, John
More informationUpdate on vitamin D. J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska USA
Update on vitamin D J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska 68131 USA Cali, Colombia 2016 definitions DRIs are the recommended dietary reference intakes
More informationUpdate on Androgen Deficiency. Acknowledgments. Curatio PowerPoint TemplateControversies in Male Hypogonadism Bradley D.
The General Practice Education Day Healthed / Generation Next August 22 nd Sydney Update on Androgen Deficiency Robert I. McLachlan, FRACP, PhD Director, Andrology Australia Principal Research Fellow,
More informationThiazolidinediones and the risk of bladder cancer: A cohort study. R Mamtani, K Haynes, WB Bilker, DJ Vaughn, BL Strom, K Glanz, JD Lewis
Thiazolidinediones and the risk of bladder cancer: A cohort study R Mamtani, K Haynes, WB Bilker, DJ Vaughn, BL Strom, K Glanz, JD Lewis Study objective To investigate the risk of bladder cancer associated
More informationTestosterone Therapy and Risk of Myocardial Infarction: A Pharmacoepidemiologic Study
Testosterone Therapy and Risk of Myocardial Infarction: A Pharmacoepidemiologic Study Mahyar Etminan, 1,2, * Sean C. Skeldon, 3,4 Sheldon Larry Goldenberg, 3 Bruce Carleton, 1,2 and James M. Brophy 5 1
More information